Revascularization/Conservative management
PreclinicalSmall molecule
Revascularization/Conservative management is one of 4 small molecule programs targeting Moyamoya disease. It is currently in Preclinical.
1
Indications
2
Total Trials
2
Active Trials
3
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
5 competitors in Moyamoya Disease
#DrugCompanyPhaseTrials
1DL-3-N-Butylphthalide
FFirst Affiliated Hospital Xi'an Jiaotong University
Phase 3
Bayer Aspirin
BayerPreclinical
Sufenta
LLeaf Vertical Inc.
Preclinical
Revascularization/Conservative management
MMinia University
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Preclinical[1]
- Company
- MMinia University